With a one year PEG ratio of 323.05, Integra Lifesciences Holdings Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 88.65% of US stocks.
With a price/earnings ratio of 103.42, Integra Lifesciences Holdings Corp P/E ratio is greater than that of about 90.29% of stocks in our set with positive earnings.
The price/operating cash flow metric for Integra Lifesciences Holdings Corp is higher than 81.74% of stocks in our set with a positive cash flow.
If you're looking for stocks that are quantitatively similar to Integra Lifesciences Holdings Corp, a group of peers worth examining would be CMD, CW, CMCO, HRC, and EPC.
IART's SEC filings can be seen here. And to visit Integra Lifesciences Holdings Corp's official web site, go to www.integralife.com.
Integra LifeSciences Holdings Corporation (IART) Company Bio
Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.
IART Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Integra Lifesciences Holdings Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Integra Lifesciences Holdings Corp ranked in the 36th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Integra Lifesciences Holdings Corp ended up being:
The company's compound free cash flow growth rate over the past 5.5 years comes in at 0.19%; that's greater than 55.66% of US stocks we're applying DCF forecasting to.
Integra Lifesciences Holdings Corp's effective tax rate, as measured by taxes paid relative to net income, is at 14 -- greater than 54.18% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 8. This value is greater than merely 20.49% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as IART, try PKI, MMSI, CRL, TMO, and A.
PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc. “Acquiring ACell and its proprietary MatriStem UBM™ technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges,” said Peter Arduini, president and CEO, Integra LifeSciences. “Together with ACell colleagues, we look forward to continuing to advance wound care innovations for our customers and patients.” Sullivan & Cromwell LLP is acting as legal advisor to Integra. About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative tissue technolo...
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN). “With this divestiture, we will now be in an even stronger position to capitalize on our core products and technologies in neurosurgery and regenerative medicine, and provide greater value to our customers and shareholders,” said Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics team for their contributions to Integra’s success and wish them all the best for their future.”Piper Sandler & Co. is serving as financial advisor and Morgan, Lewis & Bockius LLP...